Growth hormone and Insulin like growth factor -1 in relation to prostate cancer and benign prostatic hyperplasia
Keywords:
Prostate cancer, Benign prostatic hyperplasia, Growth hormone, Insulin like growth factor IAbstract
The present study investigate the role of growth hormone (GH) in the pathophysiology of prostate and the role of insulin like growth factor I (IGF-I) as a risk factor in aged male patients with prostate cancer (PCa) and benign prostatic hyperplasia (BPH). For this purpose, 40 patients with PCa and BPH (54-85 yr.), and 10 control subjects (47-75 yr.) confirmed by digital rectal examination (DRE) and prostate specific antigen (PSA) levels, were enrolled in this study. Blood samples and biopsies were collected from cases while for the control, only blood sera were used. Gleason grading system was used to determine histological pattern of Hematoxylin and Eosin stained sections. Sera GH and IGF-I were measured for all the samples using (ELISA) technique. Biopsy results revealed that 10 cases were identified as PCa with different Gleason grades (3, 4, and 5) depending on five histological patterns, and 30 cases were identified as BPH. Compared with control values, GH level was significantly higher (P< 0.05) in PCa and BPH patients, with no significant differences between PCa and BPH groups (P> 0.05) concerning serum GH level. Statistical analysis also indicates that serum levels of IGF-I was higher and significantly (P< 0.05) associated with PCa compared with controls. Serum IGF-I also showed significant difference between control and BPH patients, and between BPH and PCa patients. The present study demonstrated that the association between serum IGF-I levels and PCa was highly significant in age 60 and declined with the age (p= 0.047), but in concern to the histological grade, IGF-I showed no significant differences (p=0.894) with the progression of disease. In conclusion it's appeared that, IGF-I play an important role in the etiology of PCa and BPH.
References
Brett T. (2011): Prostate specific Antigen. Australian Family Physician. 40 (7): 497-500.
Carson FL. (19997): Histotechnology: a self-instructional text. 2nd ed pp 56, ASCP press, Chicago.
Carter HB, and Coffey DS. (1990) The prostate: an increasing medical problem. Prostate. 16: 39-48.
Chan JM., Stampfer MJ. and Giovannucci E. (1998): Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science, 279: 563-566.
Cohen P., Peehl DM., Lamson G. and Rosenfeld RG. (1991): Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab., 73: 401-407.
Copeland KC., Underwood LE. and Van Wyk JJ. (1980): Induction of immunoreactive somatomedin-C in human serum growth hormone: Dose-response relationships and effect on chromatographic profiles. J Clin Endocrinol Metab., 50: 690-697.
Daughaday WH. Rotwein P. (1989): Insulin-like growth factors I and II, peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev., 10: 68-91.
Djavan B., Waldert M., Seitz C. and Marberger M. (2001): Insulin like growth factors and prostate cancer. World J Urol., 19: 225-233.
Gleason DF. (1990): Histologic grading of prostatic carcinoma. In: Bostwick DG (ed). Pathology of the Prostate. Churchill Livingstone: New York, pp 83-93.
Humphrey PA. (2004): Gleason grading and prognostic factors in carcinoma of the Prostate. Modern Pathology, 17: 292-306.
Jenkins PJ. and Bustin SA. (2004): Evidence for a link between IGF-I and cancer. European Journal of Endocrinology,151 S17-S22.
Jones JI., and Clemmons DR. (1995):. Insulin-like growth factors and their binding proteins: biological actions [Review]. Endocr Rev., 16: 3-34.
Kehinde EO., Akanji AO., Mojiminiyi OA., Bashir AA., Daar AS. and Varghese R. (2005): Putative role of serum insulin-like growth factor–1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men. Prostate Cancer and Prostatic Diseases, 8:84-90.
LeRoith D., Bondy C., Yakar S., Liu J. and Butler A. (2001): The somatomedin studies are undertaken. hypothesis. Endocr Rev., 22:53-74.
McNeal JE. (1978) Origin and evolution of benign prostatic enlargement. Invest Urol. 15: 340-345.
McNeal,J.E.(1988B) The prostatr gland : morphology and pathobiology. Monograph Urol., 9, 36-63.
Monti S., Di Silverio F. and Iraci R. (2001): Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. J Clin Endocrinol Metab., .86: 1700-1706.
Moschos SJ. and Mantzoros CS. (2002): The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology. 63: 317-332.
Muhammad S. M. and Waheed I. N. (2013): Prostate –specific antigen as a screening tool for benign prostate hyperplasia (BPH) and prostate cancer (PCa) in Sulaimani Provinvce. Journal of University of Zakho, 1, (A) No.2: 72-81.
N’Dow J. and Wilt TJ. (2008): Benign prostatic hyperplasia. Part 1- Diagnosis. Bmj., 336: 146-149.
Nicole M., Probst H., Hao W., Victor H. H., Goh A S., Hin-Peng L. and Mimi C. Yu. (2003): Determinants of Circulating Insulin-like Growth Factor I and Insulin-like Growth Factor Binding Protein Concentrations in a Cohort of Singapore Men and Women. Cancer Epidemiology, Biomarkers & Prevention, 12: 739-746.
Oliver SE., Barrass B. and Gunnell DJ. (2004): Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle- aged men without evidence of prostate cancer. Cancer Epidemiol Biomarkers Prev 13:163-165.
Ramsay AK. and Leung HY. (2009): Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clin. Sci. (London), 117:209-228.
Reiter E., Bonnet P., Sente B., Dombrowicz D., de Leval J., Closset J. and Hennen G. (1992): Growth hormone and prolactin stimulate androgen receptor, Insulin-like growth factor-I (IGF-1) and IGF-I receptor levels in the prostate of immature rats. Mol Cell Endocrinol., 88: 77-87.
Ricka F.G., Schallya A.V., Szalontaya L., Blocka N.L., Szepeshazia K., Nadjib M., Zarandia M., Hohlaa F., Buchholza S. and Seitz S. (2012): Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. PNAS., 109 (5): 1655–1660
Samani AA., Yakar S, and LeRoith D. (2007): The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev., 28: 20-47.
Wang Z., Prins GS., Coschigano KT., Kopchick JJ., Green JE., Ray VH., Hedayat S., Christov KT., Unterman TG. and Swanson SM.(2005): Disruption of Growth Hormone Signaling Retards Early Stages of Prostate Carcinogenesis in the C3 (1)/T Antigen Mouse. Endocrinology, 146(12):5188– 5196.
Wolk A., Mantzoros CS. and Andersson S-O. (1998): Insulin-like growth factor-I and prostate cancer risk: a population-based, case control study. J Natl Cancer Inst., 90:911–915.
Yu H. and Rohan T. (2000): Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst., 92: 1472-1489.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-SA 4.0] that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work, with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online.
